RBC Europe’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

RBC Europe’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,000	Closed	-$15.6K	–	1228
2020 Q4	$15.6K	Hold	1,000	–	–	﹤0.01%	779
2020 Q3	$9.45K	Hold	1,000	–	–	﹤0.01%	809
2020 Q2	$8.96K	Hold	1,000	–	–	﹤0.01%	790
2020 Q1	$6.37K	Hold	1,000	–	–	﹤0.01%	792
2019 Q4	$8.37K	Hold	1,000	–	–	﹤0.01%	831
2019 Q3	$9.05K	Hold	1,000	–	–	﹤0.01%	805
2019 Q2	$10.8K	Hold	1,000	–	–	﹤0.01%	791
2019 Q1	$9.54K	Hold	1,000	–	–	﹤0.01%	830
2018 Q4	$11.5K	Hold	1,000	–	–	﹤0.01%	758
2018 Q3	$16.9K	Hold	1,000	–	–	﹤0.01%	717
2018 Q2	$14.2K	Hold	1,000	–	–	﹤0.01%	760
2018 Q1	$19K	Hold	1,000	–	–	﹤0.01%	684
2017 Q4	$16.4K	Hold	1,000	–	–	﹤0.01%	735
2017 Q3	$15K	Buy	+1,000	New	+$11.1K	﹤0.01%	751

Other funds holding SGMO

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

RBC Europe's SGMO Position: Q1 2021 in Review

RBC Europe sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q1 2021, closing a stake of 1,000 shares — an estimated $15.6K sold.

RBC Europe first reported a position in SGMO in Q3 2017 and held it in 14 quarters. The position peaked at $19K in Q1 2018. 203 funds tracked by Wall St. Rank hold SGMO as of Q1 2021.

RBC Europe reported no remaining SANGAMO THERAPEUTICS INC position as of Q1 2021 after selling out during the quarter.
RBC Europe sold 1,000 SANGAMO THERAPEUTICS INC shares in Q1 2021, an estimated $15.6K.
RBC Europe first reported a position in SANGAMO THERAPEUTICS INC in Q3 2017 and held it in 14 quarters.
RBC Europe's SANGAMO THERAPEUTICS INC position peaked at $19K in Q1 2018.
203 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2021.

Based on RBC Europe's 13F filing for Q1 2021, filed 9 Nov 2023.